Gastritis OLGA-staging and gastric cancer risk: A twelve-year clinico-pathological follow-up study

Alimentary Pharmacology and Therapeutics

Volumn 31, Issue 10, 2010, Pages 1104-1111

  Rugge, M ^a,b   De Boni, M ^c   Pennelli, G ^a   De Bona, M ^c   Giacomelli, L ^d   Fassan, M ^a   Basso, D ^a   Plebani, M ^a   Graham, D Y ^e  

^a UNIVERSITY OF PADOVA   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^c Feltre Hospital   (Italy)

^d UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEPSINOGEN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; GASTRITIS; GASTROSCOPY; HELICOBACTER PYLORI; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; ITALY; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; STOMACH CANCER; COMPLICATION; HELICOBACTER INFECTION; MIDDLE AGED; PATHOLOGY; PRECANCER; RISK FACTOR; STOMACH NEOPLASMS;

ADULT; AGED; FEMALE; FOLLOW-UP STUDIES; GASTRITIS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; ITALY; MALE; MIDDLE AGED; PRECANCEROUS CONDITIONS; PROGNOSIS; RISK FACTORS; STOMACH NEOPLASMS;

EID: 77951239904     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04277.x     Document Type: Article

References (37)

1. Correa P. The epidemiology and pathogenesis of chronic gastritis: three etiologic entites. Front Gastrointest Res 1980 6 : 98 108.
2. Graham DY. Helicobacter pylori infection in the pathogenesis of duodenal ulcer and gastric cancer: a model. Gastroenterology 1997 113 : 1983 1991.
3. Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7-14 June 1994. IARC Monogr Eval Carcinog Risks Hum 1994 61 : 1 241.
4. Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001 345 : 784 789.
5. Comfort MW. Gastric acidity before and after development of gastric cancer: its etiologic, diagnostic and prognostic significance. Ann Intern Med 1951 34 : 1331 1348.
6. Filipe MI, Munoz N, Matko I, et al. Intestinal metaplasia types and the risk of gastric cancer: a cohort study in Slovenia. Int J Cancer 1994 57 : 324 329.
7. Rugge M, Correa P, Dixon MF, et al. Gastric mucosal atrophy: interobserver consistency using new criteria for classification and grading. Aliment Pharmacol Ther 2002 16 : 1249 1259.
8. Rugge M. Secondary prevention of gastric cancer. Gut 2007 56 : 1646 1647.
9. Sung JJ, Kuipers EJ, El-Serag HB. Systematic review: the global incidence and prevalence of peptic ulcer disease. Aliment Pharmacol Ther 2009 29 : 938 946.
10. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996 20 : 1161 1181.
11. Kuipers EJ. Review article: relationship between Helicobacter pylori, atrophic gastritis and gastric cancer. Aliment Pharmacol Ther 1998 12 (Suppl. 1 25 36.
12. El-Zimaity H. Gastritis and gastric atrophy. Curr Opin Gastroenterol 2008 24 : 682 686.
13. Rugge M, Genta RM. Staging gastritis: an international proposal. Gastroenterology 2005 129 : 1807 1808.
14. Rugge M, Correa P, Di Mario F, et al. OLGA staging for gastritis: a tutorial. Dig Liver Dis 2008 40 : 650 658.
15. Granstrom M, Lehours P, Bengtsson C, Megraud F. Diagnosis of Helicobacter pylori. Helicobacter 2008 13 (Suppl. 1 7 12.
16. Rugge M, Meggio A, Pennelli G, et al. Gastritis staging in clinical practice: the OLGA staging system. Gut 2007 56 : 631 636.
17. Satoh K, Osawa H, Yoshizawa M, et al. Assessment of atrophic gastritis using the OLGA system. Helicobacter 2008 13 : 225 229.
18. Broutet N, Plebani M, Sakarovitch C, Sipponen P, Megraud F. Pepsinogen A, pepsinogen C, and gastrin as markers of atrophic chronic gastritis in European dyspeptics. Br J Cancer 2003 88 : 1239 1247.
19. Dinis-Ribeiro M, Yamaki G, Miki K, Costa-Pereira A, Matsukawa M, Kurihara M. Meta-analysis on the validity of pepsinogen test for gastric carcinoma, dysplasia or chronic atrophic gastritis screening. J Med Screen 2004 11 : 141 147.
20. Miki K, Morita M, Sasajima M, Hoshina R, Kanda E, Urita Y. Usefulness of gastric cancer screening using the serum pepsinogen test method. Am J Gastroenterol 2003 98 : 735 739.
21. Ren JS, Kamangar F, Qiao YL, et al. Serum pepsinogens and risk of gastric and oesophageal cancers in the General Population Nutrition Intervention Trial cohort. Gut 2009 58 : 636 642.
22. Sipponen P, Graham DY. Importance of atrophic gastritis in diagnostics and prevention of gastric cancer: application of plasma biomarkers. Scand J Gastroenterol 2007 42 : 2 10.
23. Yanaoka K, Oka M, Yoshimura N, et al. Risk of gastric cancer in asymptomatic, middle-aged Japanese subjects based on serum pepsinogen and Helicobacter pylori antibody levels. Int J Cancer 2008 123 : 917 926.
24. Doglioni C, Wotherspoon AC, Moschini A, de Boni M, Isaacson PG. High incidence of primary gastric lymphoma in northeastern Italy. Lancet 1992 339 : 834 835.
25. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977 33 : 159 174.
26. Hamilton S, Aaltonen LA. WHO Classification. Tumours of the Digestive System. Pathology & Genetics.
27. Rugge M, Correa P, Dixon MF, et al. Gastric dysplasia: the Padova international classification. Am J Surg Pathol 2000 2 : 167 176.
28. Rugge M, Cassaro M, Di Mario F, et al. The long term outcome of gastric non-invasive neoplasia. Gut 2003 5 : 1111 1116.
29. Sobin LH, Gospodarowicz M, Wittekind C. TNM Classification of Malignant Tumours. 7th ed.
30. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005 55 : 74 108.
31. Correa P, Fontham ET, Bravo JC, et al. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. J Natl Cancer Inst 2000 92 : 1881 1888.
32. Leung WK, Lin SR, Ching JY, et al. Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication. Gut 2004 53 : 1244 1249.
33. Wong BC, Lam SK, Wong WM, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 2004 291 : 187 194.
34. Garcia SB, Park HS, Novelli M, Wright NA. Field cancerization, clonality, and epithelial stem cells: the spread of mutated clones in epithelial sheets. J Pathol 1999 187 : 61 81.
35. Fukase K, Kato M, Kikuchi S, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 2008 372 : 392 397.
36. Graham DY, Nurgalieva ZZ, El-Zimaity HM, et al. Noninvasive versus histologic detection of gastric atrophy in a Hispanic population in North America. Clin Gastroenterol Hepatol 2006 4 : 306 314.
37. Vakil N, Moayyedi P, Fennerty MB, Talley NJ. Limited value of alarm features in the diagnosis of upper gastrointestinal malignancy: systematic review and meta-analysis. Gastroenterology 2006 131 : 390 401.